Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

The project "Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia" investigates the safety and efficacy of low-dose thalidomide in managing beta thalassemia, a genetic disorder causing anemia. Conducted over two years at NIBD hospital, the study involves 54 transfusion-dependent patients aged 8-35. The primary objective is to correlate thalidomide doses with disease severity, adverse effects, and treatment response, aiming to optimize treatment strategies and reduce side effects. Data will be collected through clinical interviews and medical record reviews and analyzed using SPSS. Key variables include hemoglobin levels, leukocyte and reticulocyte counts, platelets, liver and spleen size, genetic modifiers, and transfusion frequency. Inclusion criteria are specific to beta thalassemia patients, while exclusion criteria rule out those with liver dysfunction, married patients, lactating mothers, and those with a history of thrombosis or fits.

NCT Number	NCT06490627
Lead Sponsor	National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Conditions	Fetal Hemoglobin, Thalassemia Major, Genetic Disease
Enrollment	54 participants
Start Date	2024-04-22
Primary Completion	2025-04-22 (estimated)
Study Completion	2026-04-22 (estimated)
Updated on ClinicalTrials.gov	2025-05-30